Globus Medical, Inc. $GMED Position Increased by Kennedy Capital Management LLC

Kennedy Capital Management LLC boosted its position in shares of Globus Medical, Inc. (NYSE:GMED) by 44.6% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 490,949 shares of the medical device company’s stock after purchasing an additional 151,500 shares during the period. Globus Medical accounts for approximately 0.6% of Kennedy Capital Management LLC’s portfolio, making the stock its 18th biggest position. Kennedy Capital Management LLC’s holdings in Globus Medical were worth $28,117,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. EverSource Wealth Advisors LLC increased its position in Globus Medical by 74.3% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 462 shares of the medical device company’s stock worth $27,000 after purchasing an additional 197 shares during the last quarter. Advisors Asset Management Inc. acquired a new stake in shares of Globus Medical during the 2nd quarter valued at about $28,000. First Horizon Corp bought a new stake in shares of Globus Medical in the 3rd quarter valued at approximately $31,000. Parallel Advisors LLC grew its stake in shares of Globus Medical by 45.1% in the 3rd quarter. Parallel Advisors LLC now owns 557 shares of the medical device company’s stock valued at $32,000 after buying an additional 173 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. acquired a new position in Globus Medical in the third quarter worth approximately $36,000. Hedge funds and other institutional investors own 95.16% of the company’s stock.

Insider Activity

In other news, Director Leslie V. Norwalk sold 2,000 shares of Globus Medical stock in a transaction dated Thursday, January 8th. The stock was sold at an average price of $101.10, for a total value of $202,200.00. Following the transaction, the director directly owned 10,419 shares in the company, valued at approximately $1,053,360.90. The trade was a 16.10% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP Kelly Huller sold 20,000 shares of the business’s stock in a transaction dated Wednesday, February 25th. The stock was sold at an average price of $94.50, for a total value of $1,890,000.00. The SEC filing for this sale provides additional information. Over the last ninety days, insiders have sold 35,594 shares of company stock valued at $3,332,253. 18.51% of the stock is owned by insiders.

Globus Medical Stock Up 2.2%

Shares of NYSE:GMED traded up $1.87 during trading on Friday, reaching $86.38. The stock had a trading volume of 119,492 shares, compared to its average volume of 1,320,894. The stock has a fifty day simple moving average of $90.76 and a two-hundred day simple moving average of $78.10. Globus Medical, Inc. has a 52 week low of $51.79 and a 52 week high of $101.40. The firm has a market capitalization of $11.68 billion, a price-to-earnings ratio of 21.99, a P/E/G ratio of 2.04 and a beta of 1.05.

Globus Medical (NYSE:GMED) last posted its earnings results on Tuesday, February 24th. The medical device company reported $1.28 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.06 by $0.22. The business had revenue of $826.42 million for the quarter, compared to analyst estimates of $803.29 million. Globus Medical had a net margin of 18.30% and a return on equity of 12.57%. Globus Medical’s revenue was up 25.7% compared to the same quarter last year. During the same period last year, the business posted $0.84 EPS. On average, analysts forecast that Globus Medical, Inc. will post 3.44 EPS for the current year.

Wall Street Analyst Weigh In

Several research firms have commented on GMED. Piper Sandler reissued an “overweight” rating and issued a $115.00 target price (up from $90.00) on shares of Globus Medical in a research report on Thursday, January 8th. Needham & Company LLC raised their price target on shares of Globus Medical from $112.00 to $114.00 and gave the company a “buy” rating in a report on Wednesday, February 25th. TD Cowen raised shares of Globus Medical to a “strong-buy” rating in a research note on Tuesday, January 27th. Morgan Stanley upped their price objective on shares of Globus Medical from $70.00 to $100.00 and gave the stock an “overweight” rating in a report on Tuesday, December 2nd. Finally, BTIG Research reissued a “neutral” rating on shares of Globus Medical in a research report on Tuesday, December 30th. Two research analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating and five have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $104.36.

Key Headlines Impacting Globus Medical

Here are the key news stories impacting Globus Medical this week:

• Positive Sentiment: Zacks Research materially raised EPS forecasts across quarters and years (Q4 2026, Q1–Q3 2027, FY2026 and FY2027), including lifting FY2027 to ~$4.66 and several quarterly beats vs. prior Zacks views; Zacks carries a “Strong‑Buy” on GMED — this increases earnings visibility and underpins buy‑side interest. Zacks / MarketBeat Coverage
• Positive Sentiment: Brokerage consensus remains favorable: AmericanBankingNews reports an average rating of “Moderate Buy” from covering brokerages, reinforcing demand from institutional investors. Globus Medical Given Average Rating of “Moderate Buy” by Brokerages

Globus Medical Profile

Globus Medical, Inc (NYSE:GMED) is a leading medical device company specializing in musculoskeletal solutions for spine and orthopaedic applications. Founded in 2003 by David C. Paul and headquartered in Audubon, Pennsylvania, the company develops, manufactures and markets implantable devices and surgical instruments designed to treat spinal disorders and promote bone healing. Its product portfolio encompasses solutions for minimally invasive and open surgical procedures, including interbody fusion devices, pedicle screw systems, and biologics used to enhance fusion outcomes.

In addition to its core spine business, Globus Medical has expanded into robotics and navigation systems to support precision and efficiency in the operating room.